Participaciones del usuario mugiwara - Bolsa

Foro:

Fiscalidad (1) | SOS-Deoleo (13) | Bolsa (6402) | Preferentes (2)

mugiwara 23/12/19 20:17

Ha respondido al tema Farmas USA

Para movimientos locos las ACST que habla Zoka...Rango diario de 1,20 a 3,05!Ahora estan “halt t1, news pending” Así que supongo seguirán nuevos meneos locosACST

Ir a respuesta

mugiwara 23/12/19 14:48

Ha respondido al tema Farmas USA

Para mi no es lo normal/habitual. Es bueno no porque sea un solo inversor (eso me parece irrelevante), si no porque el offering es a petición del comprador y no de la empresa (eso es lo que no es habitual):“We are excited to have completed this unsolicited financing with a premier biotechnology investor and believe it represents a major vote of confidence in our drug candidates and current pivotal programs."TGTX

Ir a respuesta

mugiwara 19/12/19 14:56

Ha respondido al tema Farmas USA

Has visto que esa basura se vende por 1.225 $ ?!?!? Y encima habrá alguien que lo pague...

Ir a respuesta

mugiwara 19/12/19 14:27

Ha respondido al tema Farmas USA

CBIOAna!!! Partnership con BIIB. Saltó la liebre...+30% ahora. O igual le puedes meter un cortoCatalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular DegenerationCatalyst to receive $15 million upfront and is eligible to receive an additional $340 million in milestones and tiered royalties up to low double digitshttps://www.globenewswire.com/news-release/2019/12/19/1962743/0/en/Catalyst-Biosciences-Announces-Global-License-and-Collaboration-Agreement-to-Develop-Pegylated-CB-2782-for-the-Treatment-of-Dry-Age-Related-Macular-Degeneration.html

Ir a respuesta

mugiwara 19/12/19 13:13

Ha respondido al tema Farmas USA

EXELPartnership con Roche Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 trial – https://ir.exelixis.com/news-releases/news-release-details/exelixis-enters-clinical-collaboration-three-phase-3-combination

Ir a respuesta

mugiwara 17/12/19 15:54

Ha respondido al tema Farmas USA

SGMOPues lo que comenté, promedio en los 8. Media en 9 bajos y a esperar sentado los 11 o comérmelas.MEIPOffering a 1,60 con mucho descuento (un 30%), si llega a esa zona estos días le meto un tirito

Ir a respuesta

mugiwara 16/12/19 15:00

Ha respondido al tema Farmas USA

Potenciales BO para el 2020 según Goldman Sachs (Srpt, Amrn, Sage, Blue, Rvnc, etc, etc)

Ir a respuesta

mugiwara 16/12/19 13:47

Ha respondido al tema Farmas USA

Sí, le ha metido un pedazo de upgrade inimaginable! Me partoOppenheimer analyst Leland Gershell raised his price target for Amarin to $8 from $7 following Friday's FDA approval of Vascepa to reduce cardiovascular event risk that came roughly two weeks ahead of its December 28 PDUFA date.AMRN

Ir a respuesta

mugiwara 15/12/19 16:10

Ha respondido al tema Farmas USA

Annual Changes to the NASDAQ Biotechnology Index40 nuevas entran, 36 salen (por ej. Nvax o Clvs)https://www.globenewswire.com/news-release/2019/12/14/1960630/0/en/Annual-Changes-to-the-NASDAQ-Biotechnology-Index.html

Ir a respuesta

mugiwara 13/12/19 22:34

Ha respondido al tema Farmas USA

AMRNPues ahí estáAMARIN WINS EXPANDED USE OF VASCEPA FROM FDAFDA approved Vascepa as an adjunctive (secondary) therapy to reduce the risk of CV events among adults with elevated TG of 150 mg/dL or higher. Patients must also have either established CV disease or diabetes and two or more additional risk factors for CV disease.

Ir a respuesta